HK1198556A1 - Prediction of outcome in patients with chronic obstructive pulmonary disease - Google Patents
Prediction of outcome in patients with chronic obstructive pulmonary diseaseInfo
- Publication number
- HK1198556A1 HK1198556A1 HK14112042.7A HK14112042A HK1198556A1 HK 1198556 A1 HK1198556 A1 HK 1198556A1 HK 14112042 A HK14112042 A HK 14112042A HK 1198556 A1 HK1198556 A1 HK 1198556A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- outcome
- prediction
- patients
- pulmonary disease
- chronic obstructive
- Prior art date
Links
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/585—Calcitonins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12001590.4A EP2637023A1 (en) | 2012-03-08 | 2012-03-08 | Prediction of outcome in patients with chronic obstructive pulmonary disease |
| PCT/EP2013/000558 WO2013131621A1 (en) | 2012-03-08 | 2013-02-26 | Prediction of outcome in patients with chronic obstructive pulmonary disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1198556A1 true HK1198556A1 (en) | 2015-05-15 |
Family
ID=47780019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK14112042.7A HK1198556A1 (en) | 2012-03-08 | 2014-11-28 | Prediction of outcome in patients with chronic obstructive pulmonary disease |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20150080246A1 (ja) |
| EP (3) | EP2637023A1 (ja) |
| JP (1) | JP6117251B2 (ja) |
| CN (1) | CN104126125B (ja) |
| BR (1) | BR112014019349A8 (ja) |
| DK (1) | DK2823314T3 (ja) |
| ES (1) | ES2631653T3 (ja) |
| HK (1) | HK1198556A1 (ja) |
| IN (1) | IN2014DN07813A (ja) |
| RU (1) | RU2688168C2 (ja) |
| WO (1) | WO2013131621A1 (ja) |
| ZA (1) | ZA201405610B (ja) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2637023A1 (en) | 2012-03-08 | 2013-09-11 | B.R.A.H.M.S GmbH | Prediction of outcome in patients with chronic obstructive pulmonary disease |
| BR112017002884A2 (pt) | 2014-08-14 | 2018-01-30 | Memed Diagnostics Ltd | ?análise computacional de dados biológicos por meio do uso de variedade e hiperplano? |
| EP3217874B1 (en) * | 2014-11-12 | 2022-03-09 | Koninklijke Philips N.V. | Apparatus and method for assessing the severity of chronic obstructive pulmonary disease, copd, in a subject |
| EP3298402A1 (en) * | 2015-05-18 | 2018-03-28 | The University of British Columbia | Methods and systems of detecting plasma protein biomarkers for diagnosing acute exacerbation of copd |
| WO2017149548A1 (en) | 2016-03-03 | 2017-09-08 | Memed Diagnostics Ltd. | Rna determinants for distinguishing between bacterial and viral infections |
| CN107229813A (zh) * | 2016-03-24 | 2017-10-03 | 深圳中迈数字医疗技术有限公司 | 实施监护的判断方法及系统 |
| WO2018060999A1 (en) * | 2016-09-29 | 2018-04-05 | Memed Diagnostics Ltd. | Methods of risk assessment and disease classification |
| JP7042279B2 (ja) * | 2017-02-02 | 2022-03-25 | ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 有害事象を示すマーカーとしてのｐｒｏａｄｍ |
| EP3610260A4 (en) * | 2017-04-12 | 2021-01-06 | ProterixBio, Inc. | COMBINATIONS OF BIOMARKERS TO MONITOR CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY AND / OR ASSOCIATED MECHANISMS |
| CN107267658B (zh) * | 2017-08-21 | 2018-11-02 | 常州市第二人民医院 | Copd诊断用分子标志物 |
| CA3075442C (en) * | 2017-09-13 | 2024-04-02 | B.R.A.H.M.S Gmbh | Pct and pro-adm as markers for monitoring antibiotic treatment |
| WO2019053124A1 (en) * | 2017-09-13 | 2019-03-21 | B.R.A.H.M.S Gmbh | PROADRENOMEDULINE AS AN INDICATOR FOR RENAL REPLACEMENT THERAPY IN SERIOUSLY PATIENT PATIENTS |
| EP3682245A1 (en) * | 2017-09-13 | 2020-07-22 | B.R.A.H.M.S GmbH | Pro-adm as a therapy monitoring marker for critcally ill patients |
| EP3502706A1 (en) * | 2017-12-20 | 2019-06-26 | B.R.A.H.M.S GmbH | Workflow for risk assessment and patient management using procalcitonin and midregional-proadrenomedullin |
| CN108424969B (zh) * | 2018-06-06 | 2022-07-15 | 深圳市颐康生物科技有限公司 | 一种生物标志物、诊断或预估死亡风险的方法 |
| CN109218131B (zh) * | 2018-09-03 | 2022-03-29 | 平安医疗健康管理股份有限公司 | 网络监控方法、装置、计算机设备和存储介质 |
| CN110850006B (zh) * | 2019-12-20 | 2020-11-20 | 河南中医药大学 | 一种慢性阻塞性肺病诊断试剂及试剂盒 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
| DK2019965T3 (en) * | 2006-05-02 | 2015-07-20 | Critical Care Diagnostics Inc | DIFFERENTIAL BETWEEN LUNG AND Cardiovascular Disease |
| DE102006046996A1 (de) * | 2006-10-01 | 2008-04-03 | Brahms Aktiengesellschaft | Diagnose von Infektionen oder Entzündungserkrankungen der Atemwege und Lunge assoziiert mit Herzinsuffizienz |
| DE102006053442A1 (de) * | 2006-11-12 | 2008-05-15 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung von Infektionen und chronischen Erkrankungen der Atemwege und Lunge mittels proVasopressin, insbesondere Copeptin oder Neurophysin II |
| DE102006060112A1 (de) * | 2006-12-20 | 2008-06-26 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM |
| US8815519B2 (en) * | 2006-12-22 | 2014-08-26 | Hvidovre Hospital | Method for predicting cancer and other diseases |
| DE102007021443A1 (de) * | 2007-05-08 | 2008-11-13 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung mittels NT-proET-1 |
| EP3093663B1 (en) * | 2008-04-18 | 2018-06-13 | Critical Care Diagnostics, Inc. | Predicting risk of major adverse cardiac events |
| ES2431358T3 (es) * | 2008-11-11 | 2013-11-26 | B.R.A.H.M.S Gmbh | Pronóstico y evaluación del riesgo en pacientes que padecen insuficiencia cardíaca mediante la determinación de la concentración de ADM |
| GB0911007D0 (en) * | 2009-06-25 | 2009-08-12 | Univ Hospital Of North Staffordshire | Analyzer apparatus and methods for lung disease |
| CN102253220B (zh) * | 2011-06-07 | 2014-04-09 | 复旦大学附属中山医院 | 用于诊断慢性阻塞性肺病急性加重期的试剂盒 |
| EP2637023A1 (en) | 2012-03-08 | 2013-09-11 | B.R.A.H.M.S GmbH | Prediction of outcome in patients with chronic obstructive pulmonary disease |
-
2012
- 2012-03-08 EP EP12001590.4A patent/EP2637023A1/en not_active Withdrawn
-
2013
- 2013-02-26 JP JP2014560266A patent/JP6117251B2/ja active Active
- 2013-02-26 IN IN7813DEN2014 patent/IN2014DN07813A/en unknown
- 2013-02-26 EP EP17000604.3A patent/EP3232201A1/en active Pending
- 2013-02-26 ES ES13707113.0T patent/ES2631653T3/es active Active
- 2013-02-26 EP EP13707113.0A patent/EP2823314B1/en not_active Revoked
- 2013-02-26 DK DK13707113.0T patent/DK2823314T3/en active
- 2013-02-26 CN CN201380009139.6A patent/CN104126125B/zh active Active
- 2013-02-26 BR BR112014019349A patent/BR112014019349A8/pt not_active Application Discontinuation
- 2013-02-26 US US14/383,744 patent/US20150080246A1/en not_active Abandoned
- 2013-02-26 RU RU2014140608A patent/RU2688168C2/ru active
- 2013-02-26 WO PCT/EP2013/000558 patent/WO2013131621A1/en active Application Filing
-
2014
- 2014-07-29 ZA ZA2014/05610A patent/ZA201405610B/en unknown
- 2014-11-28 HK HK14112042.7A patent/HK1198556A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013131621A8 (en) | 2014-06-12 |
| JP2015509596A (ja) | 2015-03-30 |
| CN104126125A (zh) | 2014-10-29 |
| EP2823314A1 (en) | 2015-01-14 |
| WO2013131621A1 (en) | 2013-09-12 |
| ZA201405610B (en) | 2015-12-23 |
| US20150080246A1 (en) | 2015-03-19 |
| JP6117251B2 (ja) | 2017-04-19 |
| IN2014DN07813A (ja) | 2015-07-10 |
| EP2823314B1 (en) | 2017-04-12 |
| DK2823314T3 (en) | 2017-07-03 |
| RU2688168C2 (ru) | 2019-05-20 |
| BR112014019349A8 (pt) | 2017-07-11 |
| EP3232201A1 (en) | 2017-10-18 |
| BR112014019349A2 (ja) | 2017-06-20 |
| RU2014140608A (ru) | 2016-04-27 |
| ES2631653T3 (es) | 2017-09-01 |
| CN104126125B (zh) | 2017-03-01 |
| EP2637023A1 (en) | 2013-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1198556A1 (en) | Prediction of outcome in patients with chronic obstructive pulmonary disease | |
| HK1211844A1 (en) | Treatment of pulmonary disease | |
| HK1201452A1 (en) | Methods of reducing risk of cardiovascular disease | |
| HK1213494A1 (zh) | 治療阿爾茨海默病及相關疾病的組合療法 | |
| EP2939022A4 (en) | BIOMARKERS OF PREMATURE BIRTH | |
| HK1203676A1 (en) | Authorization of transactions | |
| EP2913047A4 (en) | SPECIFIC THERAPEUTIC AGENT OF PULMONARY DISEASE | |
| EP2710370A4 (en) | METHODS OF DIAGNOSING AND TREATING PULMONARY DISEASES OR DISORDERS | |
| HK1200352A1 (zh) | 吡唑衍生物用於治療慢性阻塞性肺病急性惡化的用途 | |
| HK1211991A1 (en) | Chronic obstructive pulmonary disease (copd) biomarkers and uses thereof (copd) | |
| HK1213324A1 (zh) | 心力衰竭療法的選擇中的生物標記物 | |
| PL2776055T3 (pl) | Sposoby leczenia zaburzeń żołądkowo-jelitowych | |
| EP2840938A4 (en) | THERAPEUTIC CUSHION | |
| HK1203616A1 (en) | Hbv immunocomplexes for response prediction and therapy monitoring of chronic hbv patients hbv hbv | |
| EP2861244A4 (en) | TREATMENT OF SLEEP APNEA | |
| EP2756302A4 (en) | METHODS OF PREDICTING AND REDUCING THE RISK OF PREMATURE BIRTH | |
| EP2709618A4 (en) | METHOD FOR THE TREATMENT AND DIAGNOSIS OF PULMONARY ARTERIAL HYPERTENSION | |
| EP2729155A4 (en) | METHODS OF TREATING OR PREVENTING A RHUMATISMAL DISEASE | |
| EP2826479A4 (en) | TREATMENT AGENT FOR CHRONIC-OBSTRUCTIVE LUNG DISEASE | |
| GB201217330D0 (en) | Therapeutic for treating inflammatory lung disorders | |
| EP2823818A4 (en) | USE OF RUPATADINE IN THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBSTRUCTIVE CHRONIC BRONCHOPNEUMOPATHY | |
| IL233568A0 (en) | A method for treating obstructive lung disease | |
| LT2702033T (lt) | 3-karboksi-n-etil-n,n-dimetilpropan-1-amino druskos panaudojimas kardiovaskuliarinių ligų gydyme | |
| GB201101770D0 (en) | Treatment of inflammatory respiratory disease | |
| GB201201778D0 (en) | Treatment of inflammatory respiratory disease |